Business Context and Reporting Period
This Form 8-K is a current report filed by Virios Therapeutics, Inc. (not Dogwood Therapeutics, Inc., as indicated in the metadata) on August 11, 2022. The filing serves to announce the results of operations for the second quarter ended June 30, 2022. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol VIRI.
Key Financial Metrics
The filing text itself does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These details are referenced as being contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes
The filing does not provide specific details on material changes versus the prior comparable period. It solely references the issuance of a press release containing the Q2 2022 results.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risk factors, or contingencies. The filing explicitly states that the information furnished in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities under that section.
Investor Verification Checklist
- Verify the correct registrant name is Virios Therapeutics, Inc., not Dogwood Therapeutics, Inc.
- Review Exhibit 99.1 (the press release) for actual Q2 2022 financial figures, as they are absent from the 8-K body text.
- Confirm the trading symbol VIRI on the Nasdaq Capital Market.
- Note that the financial data in the referenced press release is not legally "filed" under Section 18 of the Exchange Act per the disclaimer in this report.